Seroresponses to measles and meningococcal A vaccine were similar in RotaTeq booster recipients compared to control, and RotaTeq recipients had significant increases in RV-IgA and RV-IgG concentration and seroresponse rates; the study was unable to demonstrate non-inferiority to yellow fever seroresponse (as defined by ≥4-fold increase in titer), but responses to yellow fever vaccine were inexplicably quite low in both groups, making the clinical significance of this result unclear. The gene discussed is CD79A; the disease is measles.